December 8th 2023
The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.
December 4th 2023
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Amivantamab Compared With Real-World EGFR Exon 20 NSCLC Population
April 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.
Read More
Langer Assesses Several Targeted Treatment Options in the Non–Small Cell Lung Cancer Landscape
April 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Corey J. Langer, MD, discussed the EMPOWER Lung-3 and POSEIDON trials of immunotherapy options in patients with non–small cell lung cancer.
Read More
Roundtable Discussion: Bodor Reviews Benefits, Challenges of Immunotherapy for Squamous NSCLC
April 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, J. Nicholas Bodor, MD, PhD, MPH, discussed the CheckMate 9LA regimen of nivolumab and ipilimumab plus chemotherapy for patients with advanced squamous non–small cell lung cancer.
Read More
Part A of THIO-101 Trial Shows Positive Topline Safety Data in NSCLC
April 12th 2023Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.
Read More
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKI
Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Watch
Case 2: Sequencing ALK TKIs in NSCLC
Moving on to discuss the second patient case of ALK+ NSCLC, expert panelists elucidate the sequencing ALK TKIs following progression on first-line therapy.
Watch
Roundtable Discussion: Kim Reviews the Use of Chemoradiation and Immunotherapy in NSCLC
April 6th 2023During a Targeted Oncology™ Case-Based Roundtable™, Edward S. Kim, MD, MBA, discussed with participants utilizing chemoradiation and immunotherapy for patients with non–small cell lung cancer.
Read More
Link Between Medicaid and Rates of Biomarker Testing in NSCLC
March 31st 2023Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.
Watch
In Second-Line, Atezolizumab/Cabozantinib Shows No Benefit Over SOC in NSCLC
March 31st 2023At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.
Read More
Frontline ALK TKIs in Patients With NSCLC: Treatment Selection and AE Management
Following their review of clinical trial data behind frontline ALK TKIs in NSCLC, key opinion leaders share practical insight on selection and use of these agents.
Watch
Frontline ALK TKIs in NSCLC: The CROWN Trial
Focusing on the CROWN clinical trial in ALK+ NSCLC, expert panelists consider the role of frontline lorlatinib therapy in this setting.
Watch
Frontline ALK TKIs in NSCLC: The ALTA-1L Trial
Shared perspectives on the frontline use of brigatinib therapy in ALK+ NSCLC and results from the ALTA-1L clinical trial.
Watch
Frontline ALK TKIs in NSCLC: The ALEX Study
Centering discussion on clinical trial data in ALK+ NSCLC, panelists highlight the frontline use of alectinib in the ALEX study.
Watch
NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy
A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.
Watch
Expert Perspectives on Molecular Testing in Non–Small Cell Lung Cancer
Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.
Watch
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Read More
Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLC
March 20th 2023The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer
Read More